/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of...
Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -6.98% and 89.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ikena Oncology, Inc. (IKNA) could be a great choice. It is one of the several stocks that passed through our "Recent...